Search

788 Result(s)
Sort by

We are Global Top Employer 2024

We are Global Top Employer 2024

Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
Risk of parasites in dogs

Risk of parasites in dogs

With our Parassess free online tool checker, you can assess the local parasite risks for your dog so you can protect them better.
Ruminant parasite control in a nutshell

Ruminant parasite control in a nutshell

An exclusive drug-based approach to fight worms is dying. Dr. Ray Kaplan, from Georgia University, explains five things you need to know.
Shanghai

Shanghai

Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Global Careers Page

Global Careers Page

Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
environmental sustainability commitments

environmental sustainability commitments

On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
EMPERIAL-heart-failure-toplineresults

EMPERIAL-heart-failure-toplineresults

Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
emperor-preserved-kidney-subanalysis

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Ryan Henri Rickards

Ryan Henri Rickards

Ryan Henry Rickards, a senior finance manager for US Animal Health Commercial Controlling team, highlights his career at Boehringer Ingelheim.
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
AMR_Action_Fund

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation